Welcome to our dedicated page for Seaport Therapeutics news (Ticker: SPTX), a resource for investors and traders seeking the latest updates and insights on Seaport Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seaport Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seaport Therapeutics's position in the market.
Seaport Therapeutics (SPTX)/b) will participate in several investor conferences in September 2026, featuring a company presentation and panel with Co-Founder and CEO Daphne Zohar at the Goldman Sachs Life Sciences Symposium on September 15, 2026.Seaport management plans one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, the Goldman Sachs Life Sciences Symposium on September 15, and the Deutsche Bank 2026 Healthcare Summit from September 15–17. On September 23, 2026, management will join a fireside chat at 10:00 a.m. ET during the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. Live webcasts and archived replays of Seaport’s presentations will be available via the Investors section of its website.
Seaport Therapeutics (SPTX) reported positive topline results from a Phase 1 driving simulation trial of GlyphAllo™ (SPT-300) in healthy volunteers.
The primary endpoint was met: evening dosing of 375 mg GlyphAllo did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. A key secondary endpoint was also met, as a single evening dose of 250 mg showed no next-morning driving impairment versus placebo on Day 2. A 7.5 mg dose of zopiclone, used as a positive control, produced statistically significant impairment versus both GlyphAllo and placebo, confirming assay sensitivity. GlyphAllo was well-tolerated at all doses with no serious adverse events reported. Seaport plans to submit the data to the FDA and is enrolling BUOY-1, a potentially registration-enabling Phase 2b MDD trial, with topline data expected in the first half of 2027.
Seaport Therapeutics (SPTX) reported positive topline results from a Phase 1 driving simulation trial of its oral neurosteroid prodrug GlyphAllo (SPT-300) in 33 healthy volunteers.
The primary endpoint was met: evening dosing of 375 mg GlyphAllo did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. A key secondary endpoint was also met, showing that a single evening dose of 250 mg did not impair next-morning driving on Day 2 versus placebo. Driving performance was measured by Standard Deviation of Lateral Position (SDLP) using a validated Cognitive Research Corporation Driving Simulator-MiniSim.
Zopiclone 7.5 mg, used as a positive control, produced statistically significant impairment versus both GlyphAllo and placebo on Days 2 and 5, confirming assay sensitivity. GlyphAllo was well-tolerated at all doses, with mostly mild, transient adverse events and no serious adverse events. Seaport plans to submit the results to the U.S. FDA and is enrolling the potentially registration-enabling Phase 2b BUOY-1 MDD trial, with topline data expected in the first half of 2027.
Seaport Therapeutics (Nasdaq: SPTX) announced that its management team will participate in two investor events in September 2026. The company will attend the 21st Annual Wells Fargo Healthcare Conference from September 8–10, 2026, where it plans to hold one-on-one investor meetings.
Seaport will also join Citi’s 2026 Biopharma Back to School Conference from September 9–10, 2026, including a fireside chat on September 9, 2026 at 1:00 p.m. ET and one-on-one investor meetings. A live webcast and archived replay of the Citi fireside chat will be available in the Investors section of Seaport’s website.
Seaport Therapeutics (Nasdaq: SPTX) reported second quarter 2026 results and clinical updates. Cash, cash equivalents and investments totaled $427.3 million at June 30, 2026, supported by an upsized May IPO that generated $260.0 million in gross proceeds, with funding expected to support operations into 2029.
Enrollment in the Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder is ongoing, with topline data expected in 1H 2027, and a Phase 1 driving simulation study is on track for 2H 2026 data. GlyphAgo’s completed Phase 1 trial showed a 6.8-fold bioavailability increase and 10-fold lower pharmacokinetic variability versus unmodified agomelatine, with plans for Phase 2a and Phase 2b GAD trials starting in 2H 2026 and 1H 2027, respectively. Glyph2BLSD remains on track to complete first-in-human-enabling studies by year-end 2027.
R&D expenses were $24.6 million and G&A expenses $41.2 million in Q2 2026, driving a net loss of $62.6 million, largely reflecting one-time, non-cash stock-based compensation linked to the IPO.
Seaport Therapeutics (Nasdaq: SPTX) reported positive multiple-ascending dose Phase 1 data for GlyphAgo (SPT-320), an oral prodrug of agomelatine, in healthy volunteers. Seven-day dosing achieved therapeutic agomelatine exposure with reduced liver exposure, no liver-related adverse events, and no serious or severe adverse events.
Across the Phase 1 program, GlyphAgo showed dose-dependent exposure, 6.8-fold higher bioavailability, and up to 14.5-fold higher dose-normalized exposure versus oral agomelatine, with 10-fold lower PK variability. These results support planned Phase 2a and Phase 2b trials in generalized anxiety disorder, starting in 2026–2027 with topline data expected in 2028.
Seaport Therapeutics (Nasdaq: SPTX) reported Q1 2026 results and clinical progress. Cash, cash equivalents and investments were $212.6M on March 31, 2026, and an upsized IPO in May 2026 raised $260.0M in gross proceeds, funding operations into 2029.
New Phase 1 multiple-ascending dose data for GlyphAgo showed therapeutic agomelatine exposure with no liver-related adverse events. The Phase 2b BUOY-1 MDD trial of GlyphAllo is enrolling ~360 patients, with topline data expected 1H 2027. Seaport also received up to $15M in ARPA-H funding and added industry veteran Dr. Sharon Mates to its board. Q1 2026 R&D expenses were $21.4M and net loss was $25.4M.
Seaport Therapeutics (Nasdaq: SPTX) reported positive multiple-ascending dose Phase 1 data for GlyphAgo (SPT-320) in healthy volunteers. Seven-day dosing achieved therapeutic agomelatine exposures with reduced liver exposure, with no liver-related adverse events observed.
The data, including up to 14.5-fold higher exposure and lower PK variability versus agomelatine, support planned Phase 2 GAD trials starting 2026–2027.
Seaport Therapeutics (Nasdaq: SPTX), a clinical-stage neuropsychiatric therapeutics company, will participate in two investor conferences in June 2026.
The company features in a Goldman Sachs fireside chat on June 10 at 8:00 AM EDT and a UBS Virtual CNS Day fireside chat on June 15 at 10:00 AM EDT. The Goldman Sachs session will be webcast live on Seaport's investor relations site, with an archived replay available. Management will also hold one-on-one investor meetings at both events.
Seaport Therapeutics (Nasdaq: SPTX) priced an upsized initial public offering of 14,160,000 shares at $18.00 per share, generating expected gross proceeds of $254.9 million. The company granted a 30-day option to purchase an additional 2,124,000 shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026 under ticker SPTX, with the offering expected to close on May 4, 2026, subject to customary closing conditions.